Skip to content

Trial Summary

The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

Acronym:

MS200647-0005

ACTRN/NCT /ethics:

NCT03840902

Scientific title:

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

Sponsor / Cooperative group:

EMD Serono Research & Development Institute

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream Non-small Cell Lung Cancer
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2019-04-16
Anticipated End Date2028-01-26

Participating Hospitals

HospitalCalvary Central Districts Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruiting